CATALENT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.08 USD | -0.39% |
|
-1.08% | +24.82% |
| Apr. 12 | Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 | MT |
| Apr. 08 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- provision of development services and clinical supply services (55.4%);
- subcontracted manufacturing services (44.6%).
Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
56.08
USD
Average target price
63.5
USD
Spread / Average Target
+13.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.82% | 10.15B | |
| +28.79% | 676B | |
| +25.94% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +4.00% | 213B | |
| +1.92% | 207B | |
| -7.93% | 199B | |
| -10.00% | 147B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Sector Update: Health Care
